GLUE Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

$16.53  +0.25 (1.54%)
As of 12/06/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/24/2021
Outstanding shares:  46,505,914
Average volume:  133,254
Market cap:   $757,116,280
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    61225M102
ISIN:        US61225M1027
Sedol:      BP7KZP7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.08
PS ratio:   0.00
Return on equity:   -19.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy